Incyte (INCY) Income from Non-Controlling Interests (2019 - 2021)
Incyte's (INCY) quarterly Income from Non-Controlling Interests came in at $300000.0 in Q4 2021, little changed YoY from $300000.0 in Q4 2020, and down 25.0% on a QoQ basis from $400000.0 in Q3 2021.
Analysis
Incyte (INCY) Income from Non-Controlling Interests (2019 - 2021) Analysis & Trends
Incyte (INCY) has 3 years of Income from Non-Controlling Interests data on file, last reported at $300000.0 in Q4 2021.
- Quarterly Income from Non-Controlling Interests changed 0.0% year-over-year to $300000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.3 million (up 8.33% YoY) and the FY2021 annual result came in at $1.3 million, up 8.33% from the prior year.
- Income from Non-Controlling Interests declined to $300000.0 in Q4 2021, from $400000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $400000.0 in Q3 2021 to a low of $300000.0 in Q3 2019.
- A 3-year average of $310000.0 and a median of $300000.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests changed 0.0% — and 2021, when it jumped 33.33%.
- Tracing INCY's Income from Non-Controlling Interests over 3 years: stood at $300000.0 in 2019, then changed by 0.0% to $300000.0 in 2020, then changed by 0.0% to $300000.0 in 2021.
- The last three Income from Non-Controlling Interests figures came in at $300000.0 (Q4 2021), $400000.0 (Q3 2021), and $300000.0 (Q2 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 2.62 Mn |
| Sep 30, 2021 | 400,000.00 |
| Jun 30, 2021 | 300,000.00 |
| Mar 31, 2021 | 300,000.00 |
| Dec 31, 2020 | 1.58 Mn |
| Sep 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 300,000.00 |
| Mar 31, 2020 | 300,000.00 |
| Dec 31, 2019 | 4.80 Mn |
| Sep 30, 2019 | 300,000.00 |